Scarica l'app Stockscreener
30.15
2.32%
0.6874
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$29.46
Aprire:
$29.28
Volume 24 ore:
5.62M
Relative Volume:
0.51
Capitalizzazione di mercato:
$11.78B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.4533
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+7.77%
1M Prestazione:
+21.69%
6M Prestazione:
+13.02%
1 anno Prestazione:
-27.94%
Intervallo 1D:
$28.66
$30.30
Intervallo di 1 settimana:
$26.89
$30.43
Portata 52W:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
30.16 | 11.51B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.76 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.12 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
845.62 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.53 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.44 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna Options Trading: A Deep Dive into Market Sentiment - Benzinga
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders - GuruFocus
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Morris County NJ News | Daily Record
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells 23,853 Shares of Stock - MarketBeat
Noubar Afeyan, Moderna director, sells $703k in MRNA stock - Investing.com
Moderna’s new COVID vaccine receives positive CHMP opinion By Investing.com - Investing.com India
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine - GuruFocus
Moderna’s new COVID vaccine receives positive CHMP opinion - Investing.com
Moderna (NASDAQ: MRNA) COVID shot mNEXSPIKE backed by EMA panel for EU nod - Stock Titan
Big COVID-19 Vaccine Update: Pfizer, Moderna Nearing Finish Line - cbn.com
Moderna on track to extend gains for the seventh straight trading day - MSN
Moderna to Host Investor Event – Analyst Day - York Dispatch
Bellevue Group AG Has $34.18 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Banque Transatlantique SA Cuts Position in Moderna, Inc. $MRNA - MarketBeat
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts - TipRanks
Moderna (NASDAQ:MRNA) Director Sells $13,910.40 in Stock - MarketBeat
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says - Proactive financial news
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Morningstar
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike - TradingView
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges - GuruFocus
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
MRNA: Jefferies Initiates Coverage with Hold Rating and $30 PT | - GuruFocus
Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target - marketscreener.com
Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell - TradingView — Track All Markets
Jefferies initiates Moderna stock with Hold rating, $30 price target - Investing.com
Moderna Stock On Fire: Up 23% With 7-Day Winning Streak - Trefis
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? - Stocktwits
Petition claims FDA oops! means COVID-19 vaccines misbranded - BioWorld MedTech
Moderna protects you from illness and poor vaccine information - WSBT
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.? - GuruFocus
Moderna (MRNA) Q1 2025 Earnings Call Transcript - The Globe and Mail
Covid Shots Slash ER Visits for Kids in CDC Study - Bloomberg.com
Is the Market Bullish or Bearish on Moderna Inc? - Benzinga
Moderna signs deal worth up to $503m with Nanexa - Pharmaceutical Technology
Moderna and Super Micro top S&P 500 short interest list — are they ripe for a squeeze? - MSN
Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update - Finviz
US in "big danger" of falling behind in vaccine tech amid funding cuts, skepticism: Moderna co-founder - Seeking Alpha
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewswire Inc.
Moderna Founder Warns US Doubts on Science Threaten Biotech Edge - Bloomberg.com
Moderna Stock Rockets 21% With 6-Day Winning Streak - Trefis
Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products - TradingView — Track All Markets
Researchers Identify Immune Trigger Behind Myocarditis After Covid Vaccination - Bloomberg.com
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Ames Tribune
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Livingston Daily
First Trust Advisors LP Has $34.02 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
FDA investigating possible adult deaths from COVID-19 vaccines - The Lewiston Tribune
Amundi Sells 425,861 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Under Scrutiny as FDA Investigates Vaccine Safety - GuruFocus
FDA examines possible adult deaths from Covid-19 shots in probe - The Straits Times
FDA expands COVID-19 shot safety probe to include adultsreport - Seeking Alpha
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):